Current Concepts in Alzheimer's Disease: A Multidisciplinary Review

被引：211

作者：

Minati, Ludovico ^{[1
,2
]}

Edginton, Trudi ^{[4
]}

Bruzzone, Maria Grazia ^{[2
]}

Giaccone, Giorgio ^{[3
]}

机构：

[1] Fdn IRCCS, Ist Nazl Neurol Carlo Besta, Sci Direct Unit, I-20133 Milan, Italy

[2] Fdn IRCCS, Ist Nazl Neurol Carlo Besta, Neuroradiol Units, I-20133 Milan, Italy

[3] Fdn IRCCS, Ist Nazl Neurol Carlo Besta, Neuropathol Unit, I-20133 Milan, Italy

[4] Univ Westminster, Cognit Sci Res Unit, London W1R 8AL, England

来源：

AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS | 2009年 / 24卷 / 02期

关键词：

Alzheimer's disease; neuropathology; neuropsychological testing; neuroimaging; pharmacotherapy; MILD COGNITIVE IMPAIRMENT; AMYLOID PRECURSOR PROTEIN; NERVE GROWTH-FACTOR; HORMONE REPLACEMENT THERAPY; EXECUTIVE FUNCTION DEFICITS; PLACEBO-CONTROLLED TRIAL; CEREBROSPINAL-FLUID TAU; SEMANTIC MEMORY DEFICIT; VERBAL-LEARNING TEST; FACTOR GENE-THERAPY;

D O I：

10.1177/1533317508328602

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

This comprehensive, pedagogically-oriented review is aimed at a heterogeneous audience representative of the allied disciplines involved in research and patient care. After a foreword on epidemiology, genetics, and risk factors, the amyloid cascade model is introduced and the main neuropathological hallmarks are discussed. The progression of memory, language, visual processing, executive, attentional, and praxis deficits, and of behavioral symptoms is presented. After a summary on neuropsychological assessment, emerging biomarkers from cerebrospinal fluid assays, magnetic resonance imaging, nuclear medicine, and electrophysiology are discussed. Existing treatments are briefly reviewed, followed by an introduction to emerging disease-modifying therapies such as secretase modulators, inhibitors of Abeta aggregation, immunotherapy, inhibitors of tau protein phosphorylation, and delivery of nerve growth factor.

引用

页码：95 / 121

页数：27

共 329 条

[1] The EEG as indicator of the cholinergic deficit in Alzheimer's disease [J].

Adler, G .

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2000, 68 (08) :352-356

[2] A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease [J].

Aisen, P. S. ;

Saumier, D. ;

Briand, R. ;

Laurin, J. ;

Gervais, F. ;

Tremblay, P. ;

Garceau, D. .

NEUROLOGY, 2006, 67 (10) :1757-1763

[3] Alzhemed: A potential treatment for Alzheimer's disease [J].

Aisen, Paul S. ;

Gauthier, Serge ;

Vellas, Bruno ;

Briand, Richard ;

Saurnier, Daniel ;

Laurin, Julie ;

Garceau, Denis .

CURRENT ALZHEIMER RESEARCH, 2007, 4 (04) :473-478

[4] CORNELL SCALE FOR DEPRESSION IN DEMENTIA [J].

ALEXOPOULOS, GS ;

ABRAMS, RC ;

YOUNG, RC ;

SHAMOIAN, CA .

BIOLOGICAL PSYCHIATRY, 1988, 23 (03) :271-284

[5]

Alsop DC, 2000, ANN NEUROL, V47, P93, DOI 10.1002/1531-8249(200001)47:1<93::AID-ANA15>3.0.CO

[6]

2-8

[7]

Alzheimer A., 1907, Allg. Z. Psychiatr. Psych.-Gerichtl. Med., V18, P177, DOI [DOI 10.1002/CA.980080612, 10.1002/ca.980080612]

[8]

American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders: DSM-5, V5th ed., DOI DOI 10.1176/APPI.BOOKS.9780890425596

[9] Evidencing inhibitory deficits in Alzheimer's disease through interference effects and shifting disabilities in the Stroop test [J].

Amieva, H ;

LaFont, S ;

Rouch-Leroyer, I ;

Rainville, C ;

Dartigues, JF ;

Orgogozo, JM ;

Fabrigoule, C .

ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 2004, 19 (06) :791-803

[10]

[Anonymous], 1992, ICD 10 CLASS MENT BE

← 1 2 3 4 5 6 7 8 9 10 →